Advice

following an abbreviated submission:

trientine tetrahydrochloride (Cuprior®) is accepted for use within NHSScotland.

Indication under review: the treatment of Wilson's disease in adults, adolescents and children ≥5 years intolerant to D-penicillamine therapy.

Trientine tetrahydrochloride is an alternative to another formulation of trientine with a lower budget impact.

Download detailed advice438KB (PDF)

Download

Medicine details

Medicine name:
trientine tetrahydrochloride (Cuprior)
SMC ID:
SMC2222
Indication:

For the treatment of Wilson's disease in adults, adolescents and children ≥ 5 years intolerant to D-penicillamine therapy.

Pharmaceutical company
GMP-Orphan United Kingdom Ltd
BNF chapter
Nutrition and blood
Submission type
Abbreviated
Status
Accepted
Date advice published:
11 November 2019